After being informed about the study and risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry.~At baseline patients who meet the eligibility requirements will be randomised in a double- blinded manner (patient and investigator) in a 1:1 ratio to nicotinamide riboside (1000 mg daily) or placebo (once a day)
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.~The main question it aims to answer is:~• Does NR delay disability progression in progressive multiple sclerosis?~Participants will be treated with NR or placebo for 30 months,